News of Note—Freenome bumps up series A to $72M; NxStage wins FDA nod for solo home dialysis

newspaper

> Freenome raised an additional $7 million in series A funding, bringing its total to $72 million. In March, the liquid biopsy player raised $65 million in a round led by Andreessen Horowitz. Release

> The FDA cleared NxStage’s system for solo home dialysis. Patients may now perform hemodialysis at home, without a care partner, during waking hours. Release

> MedGenome bagged $30 million in series C financing—the company will ramp up biomarker discovery programs and further the development of its OncoPept suite of immunotherapy biomarker solutions. Release